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A Weighted False Discovery Rate
Control Procedure Reveals Alleles at FOXA2
that Influence Fasting Glucose Levels
Chao Xing,1,2,* Jonathan C. Cohen,1 and Eric Boerwinkle3
Association signals in GWAS are usually prioritized solely by p values. Here, we attempt to improve the power of GWAS by using
a weighted false discovery rate control procedure to detect associations of low-frequency variants with effect sizes similar to or even larger
than those of common variants. We used the Affymetrix Genome-Wide Human SNPArray 6.0 to test for association with fasting glucose
levels in the Atherosclerosis Risk in Communities Study (ARIC) population. In addition to ﬁnding several previously identiﬁed sequence
variations, we identiﬁed a low-frequency variant (rs1209523; minor allele frequency ¼ 0.043) near FOXA2 that was associated with fast-
ing glucose levels in European Americans (EAs) (n ¼ 7428, p value ¼ 1.3 3 105). The association between rs1209523 and glucose levels
was also signiﬁcant in African Americans (AAs) (n ¼ 2029, p value ¼ 6.7 3 103) of the ARIC and was conﬁrmed by replication in both
EAs and AAs of the Dallas Heart Study (n¼ 963 and 1571, respectively; p values¼ 5.33 103 and 5.83 104, respectively) and in EAs of
the Cooper Center Longitudinal Study (n ¼ 2862; p value ¼ 1.6 3 102). A meta-analysis of these ﬁve populations yielded an estimated
effect size of 1.31 mg/dl per minor allele (p value ¼ 2.2 3 1011). This study reveals that there is a cache of less-frequent variants in
GWAS arrays that can be identiﬁed via analytical approaches accounting for allele frequencies.GWAS have identiﬁed hundreds of loci associated with
common complex traits and diseases.1 Despite the explo-
sive growth of discoveries in the past few years, the
common variants identiﬁed by GWAS typically have
modest effect sizes and account for only a small fraction
of the heritability of complex traits.2,3 Two major factors
underlie the low power of detecting associations between
low-frequency variants and complex traits in GWAS. First,
the commercially available marker arrays that are used in
GWAS are designed to capture common variants. Second,
conventional statistical methods currently employed to
analyze GWAS data equally weight each hypothesis and
prioritize the signals purely by the p values obtained.
Various strategies have been proposed to uncover the
full allelic spectrum of complex traits. One approach has
been to enhance the power of GWAS by increasing sample
sizes, enhancing the coverage of common variants, and
improving phenotype deﬁnition and assessments.2,4,5
Another approach has been to shift the focus to genome
resequencing to detect rare variants with large effect sizes.6
We have focused on developing new strategies to use
the existing data of GWAS to identify less-frequent vari-
ants that contribute to common complex traits. For the
purposes of the current study, we deﬁned common
variants as SNPs with a minor allele frequency (MAF) R
5%, which is consistent with that of the International
HapMap Consortium.7,8 SNPs with a MAF < 5% were
classiﬁed as less-frequent variants. Aweighted-Holm proce-
dure,9 which is a Bonferroni-type multiple-testing correc-
tion technique, had been proposed to account for allele
frequencies in GWAS.10 Here, we employed a weighted1DonaldW. Reynolds Cardiovascular Clinical Research Center, McDermott Cen
University of Texas Southwestern Medical Center, Dallas, TX 75390-8591, USA
ton, TX 77030, USA
*Correspondence: chao.xing@utsouthwestern.edu
DOI 10.1016/j.ajhg.2010.01.025. ª2010 by The American Society of Human
440 The American Journal of Human Genetics 86, 440–446, March 1false discovery rate (FDR) control procedure11 to enhance
the power of detecting associations between less-frequent
variants and fasting glucose levels in the Atherosclerosis
Risk in Communities Study (ARIC)12 genotyped with the
Affymetrix Genome-Wide Human SNP Array 6.0.13
We ﬁrst examined the distribution of allele frequency of
autosomal SNPs in data provided by Affymetrix for the
HapMap samples,14 focusing on the Yoruba samples from
Ibadan, Nigeria (YRI) and the European American samples
from Utah, USA, of the Centre d’Etude du Polymorphisme
Humain collection (CEU), and in data from the ARIC study
including 8862 European Americans (EAs) and 2573
African Americans (AAs). In each population of the ARIC
study, SNPs were excluded if they were monomorphic or
singletons or if they had > 10% missing genotypes or
signiﬁcant deviation from the Hardy-Weinberg equilib-
rium (p value % 1.0 3 104 by the exact test15). After
data cleaning, 814,004 SNPs remained in the EAs and
818,899 SNPs remained in the AAs. Although the SNP
Array 6.0 was designed primarily for capturing common
SNPs, considerable information can be gleaned regarding
less-frequent SNPs, nonsynonymous SNPs (nsSNPs) in
particular (Tables S1 and S2, available online). Signiﬁcant
concordance was observed in the MAF distributions of
SNPs between EA and CEU and between AA and YRI,
which suggests that MAFs from appropriate reference pop-
ulations can be used as weights in GWAS employing the
weighed procedure proposed in this study.
Because the MAF appears to be inversely related to the
proportion of functional SNPs,16–18 we took the less-
frequent nsSNPs as candidate functional variants andter for HumanGrowth andDevelopment, 2Department of Clinical Sciences,
; 3Human Genetics Center, University of Texas Health Science Center, Hous-
Genetics. All rights reserved.
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Table 1. The Average Degree of Linkage Disequilibrium, r2,
between Less-Frequent Nonsynonymous SNPs and Neighboring
SNPs from the Affymetrix Genome-Wide Human SNP 6.0 Array
Stratified by MAF in the ARIC Data
MAF EA AA
(0, 0.05) 0.124 0.084
[0.05, 0.10) 0.031 0.037
[0.10, 0.20) 0.016 0.016
[0.20, 0.30) 0.011 0.016
[0.30, 0.40) 0.009 0.018
[0.40, 0.50] 0.008 0.019
Abbreviations are as follows: MAF, minor allele frequency; EA, European Amer-
ican; AA, African American.compared the performance of neighboring SNPs with
different MAFs to tag these SNPs. The neighboring SNPs
were deﬁned as the SNPs that were within 8 kilobases
(kb) and 4 kb of a less-frequent nsSNP in the EA population
and the AA population, respectively. The interval was
chosen because the average length of haplotype blocks
was 16.3 kb in CEU and 7.3 kb in YRI.8 An inverse relation-
ship was found between the MAFs of neighboring SNPs
and the degree of linkage disequilibrium (LD), measured
by r2; the less-frequent nsSNPs were best tagged by less-
frequent SNPs (Table 1). Note that we speciﬁcally used r2
instead of other measures of LD because it is a correlation
coefﬁcient,19 analogous to the metrics typically used in
GWAS. This result suggests that the less-frequent SNPs
are potentially valuable in identifying low-frequency
causal variants in genetic association studies.
To demonstrate the value of less-frequent variants in
GWAS, we performed a genome-wide association scan on
fasting glucose levels in the EA population of the ARIC
study, using the 814,004 autosomal SNPs that passed theThe Ameriquality control. A total of 7428 individuals remained in
the analysis after removal of diabetic individuals and those
without phenotype information. A total of 1200 ancestry-
informative markers (AIMs) uniformly distributed across
the genome were selected,20–22 and principal components
analysis on these SNPs was performed for the purpose of
adjusting for population stratiﬁcation.23 Association
between the trait and each SNP was tested by a linear
regression model incorporating age, sex, body mass index,
and the ﬁrst two eigenvectors from principal components
analysis of AIMs as covariates. The genotypic value was
coded in an additive genetic model, with 0, 1, and 2 denot-
ing major allele homozygote, heterozygote, and minor
allele homozygote, respectively. Because the distribution
of fasting glucose levels was skewed, a Box-Cox power
transformation24 (l ¼ -0.71) was applied to the trait. The
quantile-quantile plot indicates no systematic deviation
from the null distribution, and the inﬂation factor25 is
1.03 (Figure 1).
We compared the results of three procedures controlling
for the global type I error (Table 2, Table S3). The Bonfer-
roni correction was used to control the family-wise error
rate at the level of 0.05. With this procedure, a nominal
p value less than or equal to 6.14 3 108 was required to
declare signiﬁcance. There were 29 SNPs, located in four
genomic regions (2q24.3, 7p13, 11q21, and 13q21.32),
that met this criterion. The Benjamini and Hochberg
(BH) procedure26,27 was used to control the FDR at the
level of 0.05, and an additional SNP, located at 2q24.3,
was found (p value ¼ 9.1 3 108). Thirdly, aiming to
detect less-frequent variants associated with the trait, we
employed a weighted BH (WBH) procedure11 by weighting
each hypothesis according to the MAF of each SNP such
that a hypothesis with a lower MAF received a greater
weight. TheMAFs were obtained from the Affymetrix refer-
ence population of European descent. For those with MAFFigure 1. A Genome-wide Scan of
Plasma Fasting Glucose Levels in the EA
Population of the ARIC
Quantitle-quantile plot and scatterplot of
p values. The black horizontal line denotes
a p value of 6.14 3 108 corresponding to
the Bonferroni-corrected p value of 0.05.
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Table 2. Comparison of Three Procedures Controlling for Global
Type I error in the Genome-wide Scan of Fasting Glucose Levels in
the EA Population of the ARIC
Region
Candidate
Gene(s)
Total
SNPsa MAFb
No. of SNPs Identified
Bonferroni BH WBH
2p23.3 GCKR 1 0.40 0 0 1
2q24.3 G6PC2,
ABCB11
19 0.29 ~0.48 17 18 19
4q31.23 NR3C2 1 0.072 0 0 1
6p12.3 RUNX2 1 0.28 0 0 1
7p13 GCK 4 0.17 ~0.22 4 4 4
11q21 MTNR1B 8 0.28 ~0.43 7 7 8
13q21.32 PCDH9 1 0.00018 1 1 1
20p11.21 FOXA2 1 0.042 0 0 1
Total 36 29 30 36
The Bonferroni correction procedure controls the family-wise error rate at 0.05,
whereas both the BH and WBH procedures control the FDR at 0.05. Abbrevia-
tions are as follows: MAF, minor allele frequency; BH, Benjamini and Hochberg
procedure; WBH, weighted Benjamini and Hochberg procedure.
a The number of significant SNPs in each region obtained with the use of the
three procedures. The numbers are identical to those of the WBH procedure in
this study.
b The range of MAF for all of the significant SNPs (column 2) in each region
calculated in the EA population of the ARIC.equal to zero in the reference population, we set them as
0.0001. For each SNP iwithMAF fi, in which i˛ {1, 2,.,m}
andm is the total number of SNPs, we deﬁned its weight as
wi ¼ ðm=fiÞ=ð
Pm
j¼1
1=fjÞ such that
Pm
i¼1
wi ¼ m. Controlling the
FDR at the 0.05 level by the WBH procedure, we identiﬁed
six more SNPs that met the selection criterion, in addition
to those that we had found by using equal weights; we
identiﬁed a total of 36 SNPs, located in eight genomic
regions (2p23.3, 2q24.3, 4q31.23, 6p12.3, 7p13, 11q21,
13q21.32, and 20p11.21). Among the eight regions, four
(2p23.3, 2q24.3, 7p13, and 11q21) have been previously
reported to be associated with fasting glucose levels at
a genome-wide signiﬁcance level in other GWAS,28–34
and the other four have not been previously reported to
be associated with the trait.
We tested association of the four SNPs (rs6816503,
rs1928529, rs1442017, and rs6048209) identiﬁed as the
genome-wide signiﬁcance level in these four newly discov-
ered regions with fasting glucose levels in the AA popula-
tion of the ARIC study, using the same model that we
used in the EA population. The only signiﬁcant SNP is
rs6048209 (MAF ¼ 0.042 and 0.39 in EAs and AAs, respec-
tively) at 20p11.21 (p value ¼ 5.4 3 103). We were not
able to design a real-time PCR assay to replicate
rs6048209 in other populations. Therefore, we chose
another SNP, rs1209523 (MAF ¼ 0.043 and 0.37 in EAs
and AAs, respectively), which is in strong LD (r2 ¼ 1.00
and 0.86 in the HapMap CEU data and ARIC EAs, respec-
tively) with and close (~3.1 kb) to rs6048209, for replica-
tion (Figure 2, Table 3). The SNP rs1209523 is associated442 The American Journal of Human Genetics 86, 440–446, March 1with fasting glucose levels in both EAs (p value ¼ 1.3 3
10-5) and AAs (p value ¼ 6.7 3 10-3) of the ARIC study.
We genotyped this SNP in both EAs (n ¼ 963) and AAs
(n ¼ 1,571) of the Dallas Heart Study (DHS),35 and we
conﬁrmed that it was associated with fasting glucose levels
in both ethnic groups (p values ¼ 5.3 3 10-3 and ¼ 5.8 3
10-4, respectively) after controlling for population stratiﬁ-
cation asdescribedpreviously.36This associationwas further
conﬁrmed in the EA population (n ¼ 2862, p value ¼ 1.63
10-2) of the Cooper Center Longitudinal Study (CCLS).37
The direction of effect was constant across studies (Figure 3).
A ﬁxed-effects meta-analysis of regression coefﬁcients
weighting by the inverse of the variance38 estimated the
effect size to be 1.50, 1.16, and 1.31 mg/dl per minor
allele in EAs, AAs, and all samples, respectively; the corre-
sponding p values were ¼ 4.4 3 10-7, 4.0 3 10-6, and 2.2 3
10-11, respectively. The gene FOXA2 (MIM 600288), close
to this SNP, is a potential candidate. It is highly expressed
in liver and pancreas and is known to be involved in glucose
homeostasis (for a review, see 39).
In this study, we identiﬁed associations between less-
frequent SNPs near FOXA2 and fasting glucose levels in
a genome-wide scan by weighting hypotheses on the basis
of the MAF of SNPs, such that MAFs of less-frequent SNPs
counted more in assessing the FDR. The association signal
would have been missed with the use of the Bonferroni
correction or the BH procedure that equally weights each
hypothesis to control the global type I error rate at 0.05.
Careful examination of theMAFs and effect sizes explained
the ﬁndings. Among the ﬁve regions (2p23.3, 2q24.3,
7p13, 11q21, 20p11.21) conﬁrmed to be associated with
fasting glucose levels in the EAs,28–34 the less-frequent
variant rs6048209 at 20p11.21 had the largest effect size
(Table S3), and thus it attained a compelling p value;
however, it did not meet the level of genome-wide signiﬁ-
cance unless the MAFs were taken into consideration.
Recently, the Meta-Analysis of Glucose and Insulin-related
traits Consortium (MAGIC) reported association of 16 loci
with fasting glucose levels in 46,263 individuals of Euro-
pean descent from 21 cohorts;40 however, the region
20p11.2 was not in the list. Note that all SNPs with signif-
icant p values (%1.0 3 10-4) at 20p11.21 in the ARIC EA
population have low MAFs in EA and CEU populations
(Table S4); thus, their associations are less likely to be
detected as compared to the more frequent variants given
similar effect sizes. We speculate that this might be the
reason that the association between FOXA2 and fasting
glucose levels was not detected in the previous large-scale
European-ancestry-based GWAS. There appeared to be an
inverse relationship between MAF and effect size in these
ﬁve regions. We speculate that this relationship arose
because the MAF and effect size are inversely related given
a test statistic value.41 The data in this study is insufﬁcient
to address the architecture of the trait. Compared to an
equal-weighting approach, the WBH method determines
the signiﬁcance level accounting for the MAFs without
changing the effect size estimate. Therefore, it is subject2, 2010
Figure 2. Association of SNPs at Chromosome 20p11.21 with Fasting Glucose Levels in the EA Population of the ARIC
Scatterplot of p values and LD structure of the region.to the ‘‘winner’s curse,’’ and proper correction needs to be
done in power calculation for replication studies.
We performed a proof-of-principle simulation study
based on the genetic structure of the ARIC EA data to
investigate the empirical power of the WBH method.
A quantitative trait was simulated on the basis of the ﬁve
SNPs rs780094 (MAF ¼ 0.40), rs552976 (MAF ¼ 0.35),
rs2908289 (MAF ¼ 0.17), rs10830963 (MAF ¼ 0.28), and
rs6048209 (MAF ¼ 0.04), each being the top SNP at theTable 3. Association between rs1209523 and Fasting Glucose Levels i
Study Ethnicity MAF p Value
Fasting Gluc
CC Genotype
N M
ARIC EA 0.043 1.3 3 10-5 6807 98
DHS EA 0.044 5.3 3 10-3 883 91
ACLS EA 0.037 1.6 3 10-2 2651 96
Subtotalb EA 4.4 3 10-7
ARIC AA 0.367 6.7 3 10-3 808 99
DHS AA 0.391 5.8 3 10-4 585 92
Subtotalb AA 4.0 3 10-6
Totalb EAþAA 2.2 3 10-11
MAF, minor allele frequency.
a Diabetic individuals were excluded.
b By a fixed-effects meta-analysis of regression coefficients weighting by the inve
The Ameriﬁve regions conﬁrmed to be associated with fasting glucose
levels. These ﬁve SNPs account for 3.58% of total variance
of glucose levels in the real data, the ratio of individual
contributions being 0:99: 2:40 : 1:98 : 3:36 : 1:00. To keep
this variance components structure, we simulated the
ratio of effect sizes of the corresponding variants as
0:40 : 0:64 : 0:73 : 0:80 : 1:00 according to the formula
genetic variancef effect size2 x MAFð1MAFÞ41,42 under
the assumption of an additive model at each locus andn Five Populations
ose Levels (mg/dl)a
CT Genotype TT Genotype
ean 5 SD N Mean 5 SD N Mean 5 SD
.7 5 9.0 602 97.3 5 9.0 19 86.5 5 11.0
.9 5 11.8 76 88.4 5 11.0 4 79.0 5 5.6
.7 5 11.8 211 95.8 5 12.1 0 NA
.2 5 10.1 952 98.1 5 9.7 269 97.5 5 10.1
.5 5 13.8 742 91.5 5 11.6 244 88.5 5 10.8
rse of the variance.
can Journal of Human Genetics 86, 440–446, March 12, 2010 443
Figure 3. Association between rs1209523 and Fasting Glucose
Levels In Five Populations
Table 4. Empirical-Power Comparison of Three Procedures
Controlling for Global Type I error in 1000 Genome-wide Scans
Region
Method
Bonferroni BH WBH
2p23.3 0.413 0.540 0.773
2q24.3 1.000 1.000 1.000
7p13 1.000 1.000 1.000
11q21 1.000 1.000 1.000
20p11.21 0.422 0.549 0.774
The Bonferroni correction procedure controls the family-wise error rate at 0.05,
whereas both BH and WBH procedures control the false discovery rate at 0.05.
Abbreviations are as follows: BH, Benjamini and Hochberg procedure; WBH,
weighted Benjamini and Hochberg procedure.between loci. One thousand data sets were simulated. We
performed genome-wide scans by using a linear regression
model and compared the empirical power of the three test
procedures—Bonferroni, BH, and WBH—to detect the ﬁve
regions associated with the trait at a genome-wide signiﬁ-
cance level (Table 4). The weighting function was the
same as that in the real data analysis. The results showed
that the WBH procedure greatly increased the power of
detecting association of less-frequent variants with com-
pelling p values that fell short of genome-wide signiﬁ-
cance. The power of detecting association of less-frequent
variants at 20p11.21 was 0.422 by Bonferroni correction,
and the WBH procedure increased the power to 0.774.
The results also indicated a situation in which the WBH
procedure could increase the power of detecting associa-
tion of common variants. When the signiﬁcance level of
a common variant is close to that of a less-frequent one,
threshold relaxation by the WBH procedure might lead
to declaration of signiﬁcance for both signals. The power
of detecting association of common variants at 2p23.3
was 0.413 by Bonferroni correction, and the WBH proce-
dure increased the power to 0.773.
In this study, we proposed using the WBH procedure to
increase the power of detecting association of less-frequent
variants in GWAS. Nonetheless, we wish to emphasis that
theWBH test is a prototype, not a panacea. Its properties in
GWAS should be further investigated. In this study, we
used a loss-weighting approach that places weights on
error rates according to theMAFs.11 This weighting scheme
does not change the order of hypotheses as compared to
an equal-weighting procedure, but the corresponding
adjusted p value43 is affected, with a larger weight count-
ing more in assessing FDR. As a result, not only the signal
of less-frequent SNP rs6048209 but also the signal of444 The American Journal of Human Genetics 86, 440–446, March 1common variant rs780094 (MAF ¼ 0.40) at 2p23.3, which
achieved the level of genome-wide signiﬁcance only in
extremely large samples (>35,00028) because of small
effect size, were boosted to genome-wide signiﬁcance.
Another approach is to weight the p value directly.9,44
This strategy would affect the order of hypotheses relative
to an equal-weighting procedure. It is conceivable that the
p value weighting method will be sensitive to the weight-
ing function chosen. Using the same weighting function
as that used in the loss-weighting method, the p value
weighting method detected fewer signiﬁcant SNPs than
did the loss-weighting method in tests for association
with fasting glucose levels in ARIC EAs (data not shown).
Both weighting schemes have merits, and their advantages
and disadvantages in GWAS are worth investigating.
A well-accepted threshold for genome-wide signiﬁcance
in GWAS is 5:03108, which corresponds to a family-wise
error rate of approximately 0.05, assuming ~1 million
independent hypothesis tests across the genome.45–47 To
achieve this level of signiﬁcance, a large sample size will
be required for detecting the association of less-frequent
variants, even though their effect sizes are similar to or
larger than those of common variants. However, the
heterogeneity of consortia data may impair the power of
a study, and the less-frequent variants will always be infe-
rior to the common variants to be detected as long as all
hypotheses are equally weighted. In this study, the meta-
analysis p value attained genome-wide signiﬁcance only
when all ﬁve samples were included; all signals in the 16
regions detected by the MAGIC were common variants.
Thus, weighting hypotheses by MAFs and other preknowl-
edge may provide a practical way for detecting association
of less-frequent variants, and we advocate using such
methods to reanalyze existing GWAS data, particularly
when independent samples are available for replication.
The proposed method is also applicable to meta-analysis,
provided that the samples are homogeneous in terms of
genetic background, such that MAFs from appropriate
reference populations can be used as weights. In this
study, we employed a frequentist approach; alternatively,
a Bayesian approach48,49 can be employed. To better2, 2010
handle dependence between tests caused by LD structure,
future research should incorporate a weighted version of
the FDR control procedure under dependence.27
In summary, we employed a WBH procedure to detect
less-frequent variants associated with fasting glucose levels
in a GWAS. Our primary goal was to look speciﬁcally at
less-frequent variants, which are usually discarded in
GWAS and whose association signals typically cannot
meet the genome-wide signiﬁcance by conventional
methods. We showed that considerable information on
less-frequent variants is included in a commercial array
based on randomly distributed SNP selection. Though
more complete coverage of the genome will capture more
variants of low frequency, we speculate that the issue of
low power in detecting association for less-frequent vari-
ants will remain because of sample size limitations. Efforts
to develop new methods to extract information regarding
less-frequent variants on the current arrays also have perti-
nence to the next-generation GWAS, in which larger
numbers of low-frequency variants will be included.Supplemental Data
Supplemental Data include four tables and can be found with this
article online at http://www.ajhg.org.Acknowledgments
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